Long-acting injectable antiretrovirals for HIV treatment in the ICONA cohort: physicians’ and nurses’ points of view

Cingolani, A;Tavelli, A;De Benedittis, S;Mastrorosa, I;Muccini, C;Bini, T;Carraro, A;Compagno, M;Mazzitelli, M;Guastavigna, M;Cernuschi, M;Torti, C;Antinori, A;d'Arminio Monforte, A;null, null;d'Arminio Monforte, A;Antinori, A;Antinori, S;Castagna, A;Cauda, R;Di Perri, G;Girardi, E;Iardino, R;Lazzarin, A;Marchetti, G C;Mussini, C;Quiros-Roldan, E;Sarmati, L;Suligoi, B;von Schloesser, F;Viale, P;d'Arminio Monforte, A;Antinori, A;Castagna, A;Ceccherini-Silberstein, F;Cingolani, A;Cozzi-Lepri, A;Di Biagio, A;Girardi, E;Gori, A;Lo Caputo, S;Marchetti, G;Maggiolo, F;Mussini, C;Puoti, M;Perno, C F;Torti, C;Antinori, A;Bai, F;Bandera, A;Bonora, S;Calcagno, A;Canetti, D;Castagna, A;Ceccherini-Silberstein, F;Cervo, A;Cingolani, A;Cinque, P;Cozzi-Lepri, A;d'Arminio Monforte, A;Di Biagio, A;Gagliardini, R;Giacomelli, A;Girardi, E;Gianotti, N;Gori, A;Guaraldi, G;Lanini, S;Lapadula, G;Lichtner, M;Lai, A;Lo Caputo, S;Madeddu, G;Maggiolo, F;Malagnino, V;Marchetti, G;Mondi, A;Mazzotta, V;Mussini, C;Nozza, S;Perno, C F;Piconi, S;Pinnetti, C;Puoti, M;Quiros Roldan, E;Rossotti, R;Rusconi, S;Santoro, M M;Saracino, A;Sarmati, L;Spagnuolo, V;Squillace, N;Svicher, V;Taramasso, L;Torti, C;Vergori, A;Cozzi-Lepri, A;De Benedittis, S;Fanti, I;Giotta, M;Marelli, C;Rodano', A;Tavelli, A;Cernuschi, M;Cosmaro, L;Perziano, A;Calvino, V;Russo, D;Farinella, M;Policek, N;Del Negro, V L;Augello, M;Carrara, S;Graziano, S;Prota, G;Truffa, S;Vincenti, D;Rovito, R;Giacometti, A;Costantini, A;Barocci, V;Saracino, A;Santoro, C;Milano, E;Comi, L;Suardi, C;Viale, P;Badia, L;Cretella, S;Erne, E M;Pieri, A;Quiros Roldan, E;Focà, E;Minardi, C;Menzaghi, B;Abeli, C;Chessa, L;Pes, F;Maggi, P;Alessio, L;Nunnari, G;Celesia, B M;Vecchiet, J;Falasca, K;Pan, A;Dal Zoppo, S;Segala, D;Di Pietro, M A;Costa, C;Lo Caputo, S;Ferrara, S;Bassetti, M;Pontali, E;Blanchi, S;Bobbio, N;Mazzarello, G;Lichtner, M;Fondaco, L;Piconi, S;Molteni, C;Rusconi, S;Canavesi, G;Pellicanò, G;Marchetti, G;Antinori, S;Rizzardini, G;Puoti, M;Castagna, A;Bandera, A;Bono, V;Cossu, M V;Giacomelli, A;Lolatto, R;Moioli, M C;Pezzati, L;Diotallevi, S;Tincati, C;Mussini, C;Menozzi, M;Bonfanti, P;Lapadula, G;Sangiovanni, V;Gentile, I;Esposito, V;Coppola, N;Fusco, F M;Di Filippo, G;Rizzo, V;Sangiovanni, N;Martini, S;Cattelan, A M;Leoni, D;Cascio, A;Trizzino, M;Francisci, D;Schiaroli, E;Parruti, G;Sozio, F;Messeri, D;Bonelli, S I;Lazzaretti, C;Corsini, R;Antinori, A;Cauda, R;Mastroianni, C;Sarmati, L;Latini, A;Cingolani, A;Mastrorosa, I;Lamonica, S;Capozzi, M;Camici, M;Rivano Capparuccia, M;Iaiani, G;Stingone, C;Gianserra, L;Paulicelli, J;Plazzi, M M;d'Ettore, G;Fusto, M;Coledan, I;Madeddu, G;De Vito, A;Fabbiani, M;Montagnani, F;Franco, A;Del Vecchio, R Fontana;Pasticci, B M;Di Giuli, C;Orofino, G C;Calleri, G;Di Perri, G;Bonora, S;Accardo, G;Tascini, C;Londero, A;Battagin, G;Nicolè, S;Starnini, G;Dell'Isola, S

2024-01-01

---

Abstract

Background: Implementation level of long-acting injectable agents cabotegravir/rilpivirine (LAI CAB/RPV) for human immunodeficiency virus (HIV) treatment in Italy is still not known. The aim of this study is to identify the status of implementation of LAI CAB-RPV and its barriers. Materials and methods: A cross-sectional online survey was conducted among infectious diseases (ID) physicians and nurses belonging to the ICONA network in Italy. Three validate 4-items measures were used: Acceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM) and Feasibility of Intervention Measure (FIM). Results: Out of 61 ICONA centres, 38 (62%) completed the survey: 57.9% were academic centres, 42.1% were hospital-based. In total, 104 respondents were ID physicians (57.4%), 77 were nurses (42.5%); 4.5% of all PWH followed at the 38 centres started LAI CAB/RPV at time of study. Centres taking care of >1000 PWH reported 95% application of procedures for LA implementation, higher than other centres (P = 0.009). Mean score of AIM was (16.0, standard deviation, SD, 3.3), of IAM (16.0, SD 3.0) and FIM (16.0, SD 2.9). A linear correlation was found between AIM and the number of people with HIV who started LAI CAB/RPV (25-50 versus <25, coefficient of correlation [b] 2.57, 95%CI 0.91-4.60, P = 0.004), academic versus hospital-based centres (b -1.59, 95%CI -2.76-0.110044, P = 0.007) and the absence of preliminary systematic assessment of staff (b -1.98, 95%CI -3.31-0.65, P = 0.004). Implementation barriers were not significantly different according to the number of PWH/centre. Conclusions: LAI CAB/RPV implementation was low, with a great variability according to centre size. Tailored and centre-specific interventions to address barriers and to optimize the LA treatment implementation should be designed.